More than half of a group of severely ill coronavirus patients improved after receiving an experimental antiviral drug, although there’s no way to know the odds of that happening without the drug because there was no comparison group, doctors reported Friday.

The results published by the New England Journal of Medicine are the first in COVID-19 patients for remdesivir. The Gilead Sciences drug has shown promise against other coronaviruses in the past and in lab tests against the one causing the current pandemic, which now has claimed more than 100,000 lives.

No drugs are approved now for treating the disease. At least five large studies are testing remdesivir, and the company also has given it to more than 1,700 patients on a case-by-case emergency basis.

Friday’s results are on 53 of those patients, ages 23 to 82, hospitalized in the United States, Europe, Canada and Japan. Thirty-four of them were sick enough to require breathing machines.

Story continues below advertisement

All were given the drug through an IV for 10 days or as long as they tolerated it.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

After 18 days on average,